Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer
Hereditary breast cancer (BC) accounts for about 5-10% of cases. BRCA-associated tumors have been identified as a separate group of malignant neoplasms with distinctive clinical manifestations and specific treatment features. Understanding of biological mechanisms leading to cancer in BRCA1/2 mutation carriers and discovery of potential molecular targets, such as poly (ADP-ribose) polymerase (PARP), involved in base excision repair mechanisms, led to the development of a new class of targeted drugs belonging to the PARP inhibitors group. PARP inhibition leads to the preservation of single-stranded DNA breaks, the arrest of the replication fork, and the realization of the “synthetic lethality” phenomenon due to the inability to repair double-stranded DNA breaks by homologous recombination in cells with mutations in the BRCA1/2 genes. Two randomized trials OlympiAD and EMBRACA evaluated and proved the effectiveness of PARP inhibitors in patients with metastatic BRCA-mutated HER2-negative breast cancer in comparison with standard chemotherapy. At the same time, data on the potential use of PARP inhibitors for the treatment of BRCA-mutated HER2-positive breast cancer patients are extremely limited. This article presents a clinical example of the use of olaparib in a patient with BRCA-mutated HER2-positive metastatic breast cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Медицинский совет - (2022), 9, Seite 179-184 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
L. V. Bolotina [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Brca-associated breast cancer |
|---|
| doi: |
10.21518/2079-701X-2022-16-9-179-184 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ023210222 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023210222 | ||
| 003 | DE-627 | ||
| 005 | 20230505014210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2022-16-9-179-184 |2 doi | |
| 035 | |a (DE-627)DOAJ023210222 | ||
| 035 | |a (DE-599)DOAJeb29d7aee9514c7e82e7f35e8cd03be6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a L. V. Bolotina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hereditary breast cancer (BC) accounts for about 5-10% of cases. BRCA-associated tumors have been identified as a separate group of malignant neoplasms with distinctive clinical manifestations and specific treatment features. Understanding of biological mechanisms leading to cancer in BRCA1/2 mutation carriers and discovery of potential molecular targets, such as poly (ADP-ribose) polymerase (PARP), involved in base excision repair mechanisms, led to the development of a new class of targeted drugs belonging to the PARP inhibitors group. PARP inhibition leads to the preservation of single-stranded DNA breaks, the arrest of the replication fork, and the realization of the “synthetic lethality” phenomenon due to the inability to repair double-stranded DNA breaks by homologous recombination in cells with mutations in the BRCA1/2 genes. Two randomized trials OlympiAD and EMBRACA evaluated and proved the effectiveness of PARP inhibitors in patients with metastatic BRCA-mutated HER2-negative breast cancer in comparison with standard chemotherapy. At the same time, data on the potential use of PARP inhibitors for the treatment of BRCA-mutated HER2-positive breast cancer patients are extremely limited. This article presents a clinical example of the use of olaparib in a patient with BRCA-mutated HER2-positive metastatic breast cancer. | ||
| 650 | 4 | |a brca-associated breast cancer | |
| 650 | 4 | |a parp inhibitors | |
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a her2neu amplification | |
| 650 | 4 | |a germline mutation | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a A. L. Kornietskaya |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Kachmazov |e verfasserin |4 aut | |
| 700 | 0 | |a N. S. Prizova |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Paichadze |e verfasserin |4 aut | |
| 700 | 0 | |a T. V. Ustinova |e verfasserin |4 aut | |
| 700 | 0 | |a T. I. Deshkina |e verfasserin |4 aut | |
| 700 | 0 | |a S. F. Evdokimova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2022), 9, Seite 179-184 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g number:9 |g pages:179-184 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2022-16-9-179-184 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/eb29d7aee9514c7e82e7f35e8cd03be6 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/6931 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2022 |e 9 |h 179-184 | ||